GlassScriptPhysician profile
Cheryl A Wirth
NPI 1346354701
$12,069.68
in general payments reported to CMS, 2019-2025
51 companies · $1,767 in 2025
The $1,767 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,777 · 2022: $2,706 · 2023: $2,663 · 2024: $2,156 · 2025: $1,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,535 · Education: $51.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,534.86 |
| Education | $51.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,347.47 | 2021-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,313.67 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,069.33 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,001.54 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $956.42 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Lilly USA, LLC | $833.28 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $811.84 | 2021-2025 | |
| Abbvie INC. | $760.73 | 2021-2025 | |
| Esperion Therapeutics, INC. | $431.60 | 2021-2024 | Nexletol, Nexlizet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.51 | 2021-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $258.03 | 2021-2023 | |
| Abbott Laboratories | $226.32 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Axsome Therapeutics, INC. | $218.48 | 2022-2025 | Sunosi, Auvelity |
| Jazz Pharmaceuticals INC. | $188.15 | 2021-2022 | |
| Exact Sciences Corporation | $186.19 | 2023-2025 | Cologuard Collection Kit |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Wirth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.